

PRELIMINARY MANAGEMENT REPORT



SOPHARMA GROUP

2012

01.03.2013

General information about the Group

Sopharma Group (the Group) is a leading Bulgarian producer, exporter and local distributor of pharmaceutical products with a strong presence in Eastern and South-eastern Europe, offering a wide range of prescription medicines and OTC products.

The Group operates in the following areas:

- + production of pharmaceutical products including medicines, primarily generics, herbal-based substances and food supplements, which is primarily done by Sopharma AD (the Company) and to a lesser extent by its production subsidiaries including Bulgarian Rose - Sevtopolis AD and Unipharm AD Bulgaria, Ukraine OAO Vitamins and Ivanchich and Sons D.O.O. in Serbia;
- + distribution of pharmaceuticals, medical supplies, sanitary materials, vitamins, food supplements and cosmetics, which is mainly performed by Sopharma Trading in Bulgaria and Briz SIA in Latvia;
- + production and distribution of non-pharmaceutical products, primarily medical supplies such as syringes and other disposables in medicine, which is mainly performed by Momina Krepost AD, and other complementary activities to the production of pharmaceutical products and distribution of pharmaceutical products.

Sopharma AD is a company registered in Bulgaria under the Provisions of the Commercial Act, with its registered office in Sofia, Iliensko shose street No 16.

Sopharma AD was established in 1933 with a court registration of the company from 15.11.1991, decision No 1 / 1991 of Sofia City Court. Sopharma AD is a public company under the Law on Public Offering of Securities.

The company performs the production and marketing of medicinal substances and dosage forms; research, engineering and implementation activities in the field of phytochemistry, chemistry and pharmacy. Sopharma AD performs services as a production function and related ancillary and service activity.

Controlled companies

Sopharma Group consists of Sopharma AD and 25 entities, including 23 subsidiaries, directly or indirectly controlled by the Company, and two joint ventures (Sopharma Zdrovit, Poland, currently in liquidation and Vivaton plus, Belarus).

Company	Share as at 31.12.2012 in %
Sopharma Trading AD	81.01
Bulgarian Rose Sevtopolis AD, Kazanlak, Bulgaria	52.77**
Biofarm Engineering AD, Sliven, Bulgaria	97.15
Farmalogistika AD, Sofia, Bulgaria	76.54
Elektronkomers EOOD, Sofia, Bulgaria	100.00
Sopharma Buildings REIT, Sofia, Bulgaria	42.64
Momina Krepost AD, Veliko Tarnovo, Bulgaria	51.30**
Unipharm AD, Sofia, Bulgaria	52.21**
Phyto Palauzov AD**	50.13*
OAD Vitaminy, Uman, Ukraine	99.56
Sopharma Poland LLC, Warsaw, Poland in Liquidation	60.00
Ivanchich and Sinovi DOO., Belgrade, Serbia	51.00
Sofarma Warsaw Cn.3.o.o., Warsaw, Poland	100.00
Sopharma USA Corp., Los Angeles, USA	100.00
Extab Corporation USA, Wilmington, USA	80.00
Extab Pharma Limited, Henley on Thames, Great Britain*	80.00
BRIZ ZAO, Riga, Latvia	51.00
Brititreyd SOOO, Minsk, Belarus*	50.24
Tabina SOOO, Minsk, Belarus *	47.94*
Brizpharm SOOO, Belarus**	26.01*
Allanko ODO, Belarus	25.85*
Interpharm Company ZAO, Vitebsk, Belarus	36.31
Sopharma Ukraine EOOD	100
Vivaton OOO, Belarus**	50.00
Sopharma Zdrovit JSC Warsaw, Poland in Liquidation ***	50.01

*effective share in percent

**indirect share


***joint stock company

As at 31 December 2012 the GROUP has an interest through its subsidiary Briz OOD, Latvia in the associated company Vestpharm ODO, Belarus and Alean ODO, Belarus.

Management Board

Sopharma AD has a one tier management system with a Board of Directors of five members as follows: Ognian Donev, PhD - Chairman and members Vessela Stoeva, Alexander Tchaushev, Andrey Breshkov and Ognian Palaveev. The company is represented and managed by the Executive Director Ognian Donev, PhD.

Shareholder structure as at 31 December 2012



Industrial activity

Sopharma AD and its production subsidiaries have 14 pharmaceutical plants in Bulgaria, compliant with EU regulations (another plant is under construction), one plant in Ukraine, certified by the local authorities with a certificate recognized in all CIS Member States, two in Serbia, one of which is certified by the local authorities (and another newly opened factory in Serbia for solid forms, compliant with EU regulations). With the exception of the plant in Ukraine, all production facilities have undergone procedures for certification to the European GMP.

The production of the company is carried out and developed in the following areas:

- ✚ Production of pharmaceutical products;
- ✚ Substances and preparations based on vegetable raw materials (phytochemical production);
- ✚ Veterinary vaccines;
- ✚ Infusion solutions;
- ✚ Concentrates for haemodialysis;

- + Medical disposable products for human and veterinary medicine;
- + Injection molded products for the industry, agriculture and households.
- + Finished dosage forms including
 - + Solid tablets, coated tablets, coated tablets, capsules;
 - + Galenical - suppositories, drops, syrups, unguents;
 - + Parenteral - injectables, powders for injections lyophilic

The company has more than 210 products in its portfolio: mainly generics and 15 original products, of which 12 products are phyto-based. The original products of the Company (and in particular Carsil and Tempalgin) are key contributors to its revenues from export markets, while for the domestic sales the most important products are generics, of which the leading drug is Analgin.

The product portfolio of Sopharma AD is focused on the following therapeutic areas: cardiology, gastroenterology, pain management, cough and cold, immunology and dermatology, respiratory and asthma, neurology and psychiatry, urology and gynaecology.

The most important pharmaceutical products in terms of their contribution to revenues are:

- + Carsil - original product plant-based, used to treat gastroenterological disorders (liver disease);
- + Sedal M - generic analgesic (painkiller);
- + Tempalgin - original analgesic (painkiller);
- + Analgin - generic analgesic (painkiller);
- + Broncholytin - original plant-based product used to suppress cough;
- + Methylprednisolone - generic drugs for cases of severe allergies and certain life-threatening conditions;
- + Tabex – original plant-based drug used for smoking secession
- + Tribestan – original plant-based drug used for stimulation of the male reproductive system

Distribution

Sopharma Trading is a leading distributor of pharmaceutical products and cosmetics in Bulgaria with a market share of pharmaceutical products of 21.6% (according to IMS). Sopharma Trading is the only distributor on the Bulgarian market of particular pharmaceutical products for several leading international pharmaceutical and other companies the field of healthcare such as Amgen, Astra Zeneca, GE Healthcare, Johnson and Johnson, Abbot Diagnostics, Hartmann, Novartis and Novo Nordisk.

The company offers more than 7000 products (particularly drugs, medical equipment and devices, accessories, cosmetics, vitamins and supplements) in its portfolio, including the brands of Sopharma, and holds exclusive rights for Bulgaria over brands of strategic partners such as Aboca , Colief, Jamieson, Planter's, Premax, Skincod, SVR Laboratories, US Pharmacia and Wyeth, specialized services (such as software solutions for pharmacies and advice and consulting services) and national logistics services. Sopharma Trading cooperates with more than 400 partners and 3,870 customers.

Intellectual property

Although oriented towards generic pharmaceuticals, Sopharma AD is known for many years for its traditional production of several unique products based on plant extracts obtained by self-developed extraction technologies. These products are protected in addition to trademark and patent or corporate know-how.

For the manufactured generic products Sopharma AD relies on brand names to distinguish, all of which are registered trademarks of the company.

In all the years of its existence, Sopharma AD generates and protects its intellectual property. As a result, the company owns a large number of intellectual property, most of which - registered rights (trademarks, patents, designs) and unregistered items - mainly technology.

These assets are the result of the policy of the company for product and technological improvement, and innovation in particular.

Research and development

Sopharma AD focuses its R & D mainly on generics. R & D projects are focused on finding and developing new formulas and composition or physical properties (such as formulation or tablets) of products in order to adapt them to current market needs. A strategic goal of Sopharma AD in the future is to achieve a stable result development of eight to ten new products per year.

The company mainly submitted applications for marketing authorizations of new products, including new forms of products in Bulgaria and / or export markets and for existing products into new markets.

Employees

For 2012 the average number of employees in the Sopharma Group is 3,898 (3,889 in 2011). The average number of employees in Sopharma AD for 2011 is 1,859 (1,848 in 2011), and in Sopharma Trading AD it is 680 (698 in 2011).

Training programs offered to employees of the company aim at increasing their competences. The training policy is specifically aimed at providing high professional knowledge and improving awareness related to health and safety issues.

Employees are entitled to higher remuneration, required by applicable law for overtime, night shifts and working weekends and during holidays. Employees who work in specific, harmful or dangerous conditions receive personal protective equipment and allowances.

Changes in 2012 and as at the date of publishing of this report

On 31 January 2012 the subsidiary Briz Ltd - Latvia acquired 18% of OOO Vivaton plus in Belarus. The remaining 57% will be acquired according to the contract during the period 2012 – 2013.

On 15 February 2012 the subsidiary Briz Ltd - Latvia sold its interest in its subsidiary OOO Superlats.

On 19 March 2012 the mother company opened a kindergarten for children of employees. 25 children will receive professional care in a building that is fully aligned with the requirements for childcare and has a total area of 253 m² interior. The building complies with modern European standards, and the food is prepared consistent with the age of children and requirements for proper nutrition. The investment amounted to 300,000 BGN.

On 10 April 2012 the Board of Directors of Sopharma decided to sell 51 % of the capital of ZAO Rostbalkanpharm, city of Azov, Rostov Region, Russian Federation.

On 18 April 2012 Sopharma AD received notifications of disclosure of shareholdings under Art. 145 of POSA: Gramercy Select Master Fund, USA, Georgetown sold 8,587,285 shares, representing 6.51% of the capital of Sopharma, thereby closing its position in the capital of Sopharma AD, and Gramercy Emerging Markets Fund, USA, Georgetown sold 7,980,192 shares, representing 6.05% of the capital of Sopharma, thereby closing its position in the capital of Sopharma AD. The date of registration of the two transactions with the Central Depository is 09 April 2012.

In May the Board of Directors of Sopharma AD (the “Company”) took the decision to establish the Sopharma Ukraine OOD company with headquarters in Kiev, Ukraine and with share capital of 1,000,000 / one million / UAH. The aim of the company is to optimize the trading business in Ukraine.

Sopharma received in June in Belgrade the prestigious international award "Business Partner of 2012" for the opening of a second production plant for medicines near Belgrade in September 2011.

The Annual General Meeting of shareholders of Sopharma AD, held on 19 June 2012 in Sofia, 16 Iliensko shousee, took the following decisions:

- + net profit for 2011, amounting to 40 790 563.74 BGN, after the allocation of 10% for the statutory reserve, shall be distributed as follows: 0.07 BGN (seven stotinki) shall be distributed as dividend to shareholders, the remainder shall be allocated to the additional reserves of the Company.
- + AGM dismissed Unipharm AD as a member of the Board of Directors at the request of the company and elected Mr Ognian Kirilov Palaveev as a member of the Board of Directors.
- + AGM elected the registered auditor company AFA ODD, Sofia, 38 Oborishte Str. to audit and certify the annual financial statements for 2012.

On 20 June 2012 was held an Annual General Meeting of Shareholders of Unipharm AD. The AGM decided to distribute the profit achieved in 2011 as follows: after the allocation of 10% of the profit to the legal reserves a / 1 500 000 BGN shall be distributed as dividends to shareholders or 0.25 BGN per share and b/ the remaining 583 289.74 BGN shall be allocated to the additional reserves.

The Annual General Meeting of Shareholders of Sopharma Trading AD, held on 26 June 2012, decided to distribute the profit for 2011 as follows: 641 590.73 BGN shall be allocated to the Reserve Fund, 5 593 851.53 BGN shall be distributed as dividends to shareholders – gross dividend per share is 0.17 BGN; 180 465.03 BGN shall be allocated to the additional reserves of the company.

On 28 June 2012 an Annual General Meeting of Shareholders of Sopharma Buildings REIT was held. The AGM decided to distribute the profit achieved in 2011 as follows: a/ 151 242.89 BGN shall be distributed as dividends to shareholders and b/ the remaining 17 514.17 BGN shall be allocated to the Reserve Fund. The gross dividend per share is 0.23268 BGN.

On 17 July 2012 Sopharma increased its interest in the capital of Doverie United Holding AD from 14.97% to 18.70% as a result of a capital increase of Doverie United Holding AD.

Sopharma AD increased its share in the capital of Biopharm Engineering AD from 69,43% to 97,15% after a capital increase by the company.

On 29 October 2012, pursuant to Article 262d of the Commercial Act, was signed a merger agreement between Bulgarian Rose – Sevtopolis AD (merging company) and Sopharma AD (acquiring company). The agreement settles both the technical process of the merger of Bulgarian Rose – Sevtopolis AD into Sopharma AD, as well as the ensuing consequences for the two companies. The fair price of the shares of the companies involved in the transformation is

determined based on generally accepted valuation methods. Based on the fair price of the shares of the companies involved in the transformation an exchange ratio of 0.554192 has been formed, which means that one share of the merging company Bulgarian Rose – Sevtopolis AD shall be exchanged for 0.554192 shares of the acquiring company Sopharma AD. As of the present moment the Deputy Chairman of the Financial Supervision Commission, Head of the "Investment Supervision" Department, has not yet granted an approval under art. 124 of the POSA of the merger contract, of the reports of the governing bodies under art. 262i of the Commercial Act and of the report of the examiner under art. 262 m of the Commercial Act.

On 01 November 2012 an Extraordinary Meeting of Shareholders of Sopharma was held, which took the following decision: "EGM amends the conditions for share repurchase, determined by the decision taken on item 14 of the agenda of the regular AGM, held on 23 June 2010, and amended by the decision of the Extraordinary General Meeting of Shareholders from 30 November 2011, as follows: the repurchase of own shares representing the company's capital, subject to the specific requirements of CA and POSA, shall be carried out under the following conditions: volume of treasury shares - up to 10% of the total number of shares issued by the company, but not more than 3% for one calendar year; period of execution of the repurchase – not longer than 5 (five) years; minimum repurchase price– 2.10 BGN; the maximum repurchase price of 5,50 BGN per share, determined by a decision of the regular AGM from 23 June 2010, shall not be amended."

The Board of Directors, pursuant to Article 223 of the Commercial Act, convenes an Extraordinary General Meeting of Shareholders of "Sopharma" AD, which will be held on 28 February 2013 at 11.00 AM at the Company's headquarters in Sofia, "Iliensko shosee" № 16 and in the absence of a quorum – on 15 March 2013 at the same place and time and according to the following agenda: "Amendment of the conditions for acquisition of treasury shares of the Company. Draft decision: AGM shall amend the conditions for share repurchase, determined by the decision on the regular AGM, held on 23 June 2010, and amended by decisions of the Extraordinary General Meeting of Shareholders from 30 November 2011 and the EGM from 1 November 2012, as follows: the repurchase of own shares representing the company's capital, subject to the specific requirements of CA and POSA, shall be carried out at a minimal repurchase price not lower than the nominal value of one share of the capital of the Company."

On 23 January 2013 Sopharma AD received a notification of disclosure of shareholdings under art. 145 of POSA from Financial Consulting Company EOOD for the selling of 4,053,002 shares of Sopharma, resulting in a decrease of its interest in the capital of Sopharma to 9.62%.

On 23 January 2013 Sopharma AD received a notification for disclosure of shareholdings under art. 145 of POSA from Donev Investments Holding AD for the purchasing of 2,982,666 shares of Sopharma, resulting in an increase of its participation in the capital of Sopharma to 26.78%.

New developments and products

New products in 2012

Three new products for the Company have been implemented - Vitamin C ampoules of 2 ml. and 5 ml. for oral ingestion, Sopral ampoules and Neurelaks tablets.

Expected in 2013

The implementation of 3-5 new products is expected by the end of 2013.

Developments

More than 50 production processes and technologies are in a process of transfer and optimization. Twenty-three new products for the company are currently under pharmaceutical development.

Key financial indicators

Indicators	1-12/2012 BGN '000	1-12/2011 BGN '000	change %
Sales revenue	682 134	644 731	5.8%
Earnings before interest, taxes, depreciation and amortisation (EBITDA)	67 696	65 757	3.0%
Operating profit	48 262	46 025	4.9%
Net profit	35 818	40 336	-11.2%
Capital expenditures	75 334	47 425	58.8%
	31.12.2012	31.12.2011	
	BGN '000	BGN '000	
Non-current assets	351 259	294 130	19.4%
Current assets	396 346	382 458	3.6%
Equity	390 516	365 812	6.8%
Non-current liabilities	71 707	35 102	104.3%
Current liabilities	285 382	275 674	3.5%

Ratios	1-12/2012	1-12/2011
EBITDA / Sales revenue	9,9%	10,2%
Operating profit/ Sales revenue	7,1%	7,1%
Net profit/ Sales revenue	5,3%	6,3%
Borrowed capital/ Equity	0,91	0,85
Net debt/ EBITDA, annualised	3,8x	2,8x

Review of risk factors

Risks relating to the Group's business and the industry the Group operates in

- ✚ The Group faces significant competition.
- ✚ Part of Sopharma Trading's revenues in Bulgaria are generated by sales to hospitals, which involve a higher degree of business risk.
- ✚ Reputation of the Group may be adversely affected by untrue or misleading information available on websites (www.sopharma.com) containing the name Sopharma which have not been authorized by the Company.
- ✚ The Group is dependent on regulatory approvals.
- ✚ Government regulations affecting the Group's business may change, thus possibly increasing compliance costs or otherwise affecting its operations.
- ✚ Part of the Group's revenues, in particular in Bulgaria, depend on the inclusion of the Company's medicines on reimbursement lists.
- ✚ The Company's and Group Companies' production facilities and processes are subject to strict requirements and regulatory approvals that may delay or disrupt the Group's operations.
- ✚ The Company's ability to pay dividends depends on a number of factors and there can be no assurance that the Company will be able to pay dividends in accordance with its dividend policy or at all in any given year.
- ✚ The Group is subject to operational risk which is inherent to its business activities.
- ✚ The Group is subject to numerous environmental and health and safety laws and regulations and is exposed to potential environmental liabilities.
- ✚ Litigation or other out-of-court proceedings or actions may adversely affect the Group's business, financial condition and results of operations.

Risks relating to Bulgaria and other markets in which the Group operates

- ✚ The macroeconomic environment, particularly in Bulgaria, Russia and Ukraine, has a significant effect on the Group's operations and position.
- ✚ The political environment in Bulgaria has a significant effect on the Group's operations and financial condition.
- ✚ The political environment in the Group's export markets, especially in Russia and Ukraine, has a significant effect on the Group's operations and financial condition.
- ✚ Risks related to the Bulgarian legal system.

- ✚ Risks relating to exchange rates and the Bulgarian Currency Board
- ✚ Interpretations of tax regulations may be unclear and tax laws and regulations applicable to the Group may change

Currency risk

The Group companies perform their operations with active exchange with foreign suppliers and clients and therefore, they are exposed to currency risk.

A significant volume of the Group's revenue is formed mainly through the parent company from export of finished products contracted as payable in EUR. At the same time, the Group again through the parent company supplies a small part of its basic raw materials and consumables in USD. The currency risk is related to the adverse floating of the exchange rate of USD against BGN in future business transactions as to the recognised assets and liabilities denominated in foreign currency and as to the net investments in foreign companies.

The companies abroad conduct sales mainly to the local markets, which leads to currency risk to their currencies as well – Ukrainian Grivna (UAH), Serbian Dinar (RSD), Russian Ruble (RUB), Latvian Lat (LVL), Belarus Ruble (BYR). The remaining part of Group companies' operations are usually denominated in Bulgarian Lev (BGN) or euro (EUR).

There is a currency risk control system implemented throughout the whole Group for the planning of imports, the sale in foreign currencies, as well as for procedures for daily monitoring of the movement of the USD exchange rate and control of pending payments. The exposition of the subsidiaries in Bulgaria to currency risk is insignificant, because almost all sales are conducted on the local market in BGN. The import of goods is fully conducted in EUR. The loans in foreign currencies are denominated mainly in EUR.

Credit risk

Credit risk is the risk that any of the Group's clients will fail to discharge in full and within the normally envisaged terms the amounts due under trade receivables. The latter are presented in the statement of financial position at net value after deduction of impairments related to doubtful and bad debts. Such impairments are made where and when events have existed identifying loss due to uncollectability as per the previous audit.

The Group has developed policy and procedures to assess the creditworthiness of its counterparts and to assign credit rating and credit limits to clients by group.

The financial resources of the Group as well as the settlement operations are concentrated in different first-class banks. When distributing the cash flows among them, the management of the parent company and the subsidiaries take into consideration a variety of factors, as the amount of capital, reliability, liquidity, the credit potential and rating of the bank etc.

Liquidity risk

Liquidity risk is an adverse situation where the Group encounters difficulty in unconditionally meeting its obligations within their maturity, including in the case of hyperinflation and recalculation of trade estimates for companies operating in such environment.

The Group generates and maintains a significant volume of liquid funds. An internal source of liquid funds for the Group is its main economic activity of its companies generating sufficient operational flows. Banks and other permanent counterparts represent external sources of funding. Another significant source of risk is the net position in BYR and the hyperinflation on that market.

Risk of interest-bearing cash flows

Interest-bearing assets are presented in the structure of Group's assets as cash, bank deposits and fixed interest rate loans granted. On the other hand, the Group's borrowings in the form of long-term and short-term loans are usually with a floating interest rate. This circumstance makes the cash flows of the Group partially dependent on interest risk. This risk is covered in two ways:

- (a) optimisation of resources and structure of credit resources for achieving relatively lower price of attracted funds; and
- (b) combined structure of interest rates on loans comprising two components – a fixed one and a variable one, the correlation between which, as well as their absolute value, can be achieved and maintained in a proportion favourable for the Group companies. The fixed component has a relatively low absolute value and sufficiently high relative share in the total interest rate. This circumstance eliminates the probability of a significant change in interest rate BGNs in case of variable component updating. Thus the probability for an unfavourable change of cash flows is reduced to a minimum.


The management of the Group companies together with that of the parent company currently monitor and analyse the exposure of the respective company to the changes in interest BGNels. Various scenarios are simulated taking into consideration refinancing, renewal of existing positions, and alternative financing. Based on these scenarios, the impact of a defined interest rate shift, expressed in points or %age, on the financial result and equity is calculated. For each simulation, the same assumption for interest rate shift is used for all major currencies. The calculations are made for major interest-bearing positions.

Financial results for 2012

Sales revenues

Revenues from sales of the Group have increased by 37,4 million BGN or 5,8%, reaching 682,1 million BGN in 2012 compared to 644,7 million BGN in 2011. The increase is due to an increase in sales of goods by 27,3 million BGN, reaching 424,5 million BGN in 2012 compared to 397,2 million BGN in 2011 and growth of 10,1 million BGN in sales of finished products, which reach 257,7 million BGN in 2012 compared to 247,5 million BGN in 2011 .

Sales by types of markets



The contribution of sales in Bulgaria to the consolidated sales revenue in 2012 amounted to 69%, increasing by 11,1 million BGN, or 2,4%, to 471,8 million in 2012, compared to 460,8 million BGN in 2011.

Sopharma has a 5% share of the Bulgarian pharmaceutical market in terms of value and a 13% share in terms of sales. The positions of the main competitors of the company in the country are as follows: Novartis - 7% (5% in units.), Actavis - 6% (14% in units.), Roche-6% (1% in units.), Glaxosmithkline - 6% (3% in units), Sanofi-Aventis-Zentiva - 5% (3% in units.), Servier - 4% (2% in units), Astra Zeneca - 3% (1 % in units), Pfizer - 3% (2% in units). Bayer -3% (2% in units), among the distributors of medicines Sopharma Trading AD has a relative share of 21,6% and along with

Phoenix / Libra (20,4% share) and Sting (20,6%) has a leading position in the national pharmaceutical market.

The Group products with the highest share in sales in the country are Analgin, Vicetin, Methylprednisolone, Flixotid, Vitamin C.


Export sales grew by 26,4 million BGN or 14.3%, reading 210,4 million BGN in 2012 compared to 184 million BGN in 2011.

Revenue by groups of products

Reported revenue of the Group includes the following items: revenue from the sale of finished products and revenue from the sale of goods.


Revenues from the sale of finished products include revenue from the sale of products manufactured by the Company and the Group companies.

Revenues of finished products by type	1-12/2012 BGN '000	1-12/2011 BGN '000	change %
Tablets	179 545	176 134	2%
Ampoules	33 339	28 477	17%
Syrups	15 337	17 001	-10%
Unguents	6 554	4 941	33%
Lyophilic products	5 162	5 943	-13%
Drops	4 989	3 709	35%
Syringes	2 374	2 191	8%
Infusion solutions	1 763	1 986	-11%
Other	8 609	153	20%
Total	257 672	247 535	4%



Revenues from the sale of goods include revenue from the sale of goods to third parties, which are distributed primarily by Sopharma Trading AD and Briz.

Revenues of goods by type	1-12/2012	1-12/2011	change
	<i>BGN '000</i>	<i>BGN '000</i>	%
Tablets	206 169	209 367	-1.5%
Ampoules	115 761	100 634	15%
Consumables, bandage materials and apparatuses	34 550	23 665	46%
Drops	21 081	22 151	-5%
Syrups	10 387	9 482	10%
Unguents	9 980	9 418	6%
Food supplements and herbs	9 064	4 703	93%
Other	17 470	17 776	-2%
Total	424 462	397 196	7%



Other revenues from operations

Other revenues from operations	2012	2011	change	share 2012
	<i>BGN '000</i>	<i>BGN '000</i>	%	%
Services rendered	3 064	1 854	65%	66%
Rents	734	405	81%	16%
Income from forfeits	704	782	-10%	15%
Services of social activities and events	574	559	3%	12%
Income from financing	517	433	19%	11%
Profit/ (loss) from sale of long-term assets	310	173	79%	7%
Net gains/(losses) from changes in the fair value of investment properties	116	(109)	206%	3%
Net losses from exchange rate differences on commercial receivables and payables and current accounts	(2 218)	(3 789)	41%	-48%
Other	812	1 467	-45%	18%
Total	4 613	1 775	160%	100%

Other operating income increased by 2.8 million BGN reaching 4,6 million BGN in 2012, compared to 1,8 million in 2011. The most significant influence on the increase have the decrease in net losses from exchange rate differences on commercial receivables and payables and current accounts, which decreased by 1.6 million BGN, as well as the increase in income from services rendered, which grew by 1,2 million. Profits from sale of long-term assets, gains from changes in the fair value of investment properties, rents and income from financing increased as well. Written-off receivables and profits from sale of materials decreased.

Expenses

Operating expenses	2012	2011	change	share 2012
	BGN '000	BGN '000	%	%
Changes in inventories of finished goods and work in progress	(3 582)	(10 414)	-66%	-1%
Book value of goods sold	402 542	370 991	9%	63%
Materials	87 410	86 524	1%	14%
Personnel	67 352	64 582	4%	11%
Hired services	55 128	59 336	-7%	9%
Amortisation	19 436	19 732	-2%	3%
Other operating expenses	10 199	9 730	5%	2%
Total	638 485	600 481	6%	100%

The operating expenses in 2012 increased by 38,0 million BGN or 6% from 600,5 million BGN in 2011 to 638,5 million BGN in 2012 due to growth in sales and therefore the carrying value of sold products in the internal market, increased cost of materials, personnel and other operating expenses.

Expenses on materials	2012	2011	change	share 2012
	BGN '000	BGN '000	%	%
Basic materials	62 911	64 194	-2%	72%
Spare parts, laboratory and technical materials	6 989	5 858	19%	8%
Heat power	5 123	4 501	14%	6%
Electric energy	4 813	4 262	13%	6%
Fuels and lubricating materials	3 400	3 246	5%	4%
Water	938	909	3%	1%
Security services	848	729	16%	1%
Other	2 388	2 825	-15%	3%
Total	87 410	86 524	1%	100%

Cost of materials (14% share) increased by 0,9 million BGN or 1% to 87,4 million BGN in 2012 compared to 86,5 million BGN in 2011. The cost of basic materials fell by 1,3 million BGN, or 2%,

the most significant impact is defined as the cost of substances and packaging materials which decreased accordingly by 0,7 million BGN and 1 million BGN. The cost of heat, spare parts, laboratory and technical materials and electricity increased. This increase in cost of materials is mainly due to increased volume of production.

	2012	2011	change	share 2012
	BGN '000	BGN '000	%	%
Hired services expenses				
Advertising	15 286	14 696	4%	28%
Manufacture	6 021	13 830	-56%	11%
Rentals and insurance	5 791	3 022	92%	11%
Forwarding and transportation services	4 792	4 318	11%	9%
Buildings and equipment maintenance	3 755	3 735	1%	7%
Commissions	323	3 081	-90%	1%
Consulting services	4 084	2 643	55%	7%
Bank and regulatory taxes	1 867	2 003	-7%	3%
Services under civil contracts with physical persons	1 538	1 732	-11%	3%
Subscription fees	1 511	1 213	25%	3%
Local taxes and charges	1 170	912	28%	2%
Communications	1 003	824	22%	2%
Security	1 118	883	27%	2%
Registration of medicines	1 213	958	27%	2%
Other	5 656	5 486	3%	10%
Total	55 128	59 336	-7%	100%

Hired services have a 9% share of operating expenses and decreased by 4,2 million BGN or 7%, reaching 55,1 million BGN in 2012 compared to 59,3 million BGN in 2011. The most significant influence comes from manufacture, which decrease by 7,8 million BGN, as well as a decrease of 2,8 million BGN in commission fees. The expenses which increased were rents by 2,8 million BGN, forwarding and transportation services, which rose by 0,5 million and consulting services – an increase by 1,4 million and others.

	2012	2011	change	share 2012
	BGN '000	BGN '000	%	%
Personnel costs				
Current wages and salaries	52 250	50 470	4%	78%
Social security/health insurance contributions	10 143	9 981	2%	15%
Social benefits and payments	3 632	3 196	14%	5%
Other	1 327	935	42%	2%
Total	67 352	64 582	4%	100%

Personnel costs (with an 11% share) grew by 2,8 million, or 4%, reaching 67,4 million in 2012 compared to 64,6 million BGN in 2011. Total growth of these costs is due to the increase of salaries of the personnel, as well as the profit-based bonuses of the management of the Company.

	2012	2011	change	share
	BGN '000	BGN '000	%	2012
Other operating expenses				
Entertainment allowances	2 778	2 541	9%	27.2%
Accrued/(recovered) impairment of current assets, net	1 907	2 683	-29%	18.7%
Business trips	1 610	1 446	11%	15.8%
Scrap and loss of finished products and long-term assets	1 320	783	69%	12.9%
Awards on litigations	757	5		7.4%
Donations	435	470	-7%	4.3%
Trainings	309	356	-13%	3.0%
Payments to the budget	210	567	-63%	2.1%
Other	873	879	-1%	8.6%
Total	10 199	9 730	5%	100.0%

Other operating expenses (with a share of 1.6%) increased by 0,5 million BGN or 5% from 9,7 million BGN in 2011 to 10,2 million BGN as at the end of 2012. There is an increase in scrap and loss of finished products and long-term assets by 0,5 million BGN, awards on litigations by 0,8 million BGN and entertainment allowances by 0,2 million BGN.

Depreciation costs (with a share of 3 %) decreased by 0,3 million BGN or 2% from 19,7 million BGN in 2011 to 19,4 million BGN in 2012.

Financial income and expenses

	2012	2011	change	share
	BGN '000	BGN '000	%	2012
Financial income				
Income from interest on loans granted	4 148	4 638	-11%	70%
Income from interest on overdue payments	1 056	1 467	-28%	18%
Net gain on exchange rate differences on loans	380	388	-2%	6%
Income from shares	194	80	143%	3%
Income from interest on deposits	71	440	-84%	1%
Interest on special contracts	43			1%
Total	5 892	7 013	-16%	100%


			change	share 2012
Financial expenses				
Interest expenses on loans	7 210	8 298	-13%	71%
Impairment of available-for-sale investments	3 202	2 624	22%	22%
Bank fees on loans and guarantees	520	529	-2%	5%
Financial leasing interest	320	256	25%	2%
Expenses on equity investments	15	6	150%	0%
Total	11 267	11 713	-4%	100%

Financial income is reduced by 1,1 million BGN or 16%, reaching 5,9 million BGN in 2012 compared to 7,0 million BGN in 2011. This is due to a decrease in income from interest loans granted by 0,5 million BGN, as well as a decrease in income from interest on overdue payments by 0,5 million BGN.

Financial expenses decreased by 0,4 million BGN or 4% from 11,7 million BGN in 2011 to 11,3 million BGN in 2012. This decrease is mainly due to the reduction of interest expense on borrowings by 1,1 million BGN.

Net financial income (expenses) decreased by 0,7 million BGN, reaching (5,4) million BGN in 2012 compared to (4,7) million BGN in 2011.

Financial income and expenses



Earnings before interest, taxes, depreciation and amortization (EBITDA) increased by 1,9 million BGN or 3%, amounting to 67,7 million BGN in 2012, compared to 65,8 million BGN in 2011.

Operating profit increased by 2,3 million BGN or 5%, to 48,3 million BGN in 2012 compared to 40 million BGN in 2011.

Net profit decreased by 4,5 million BGN, or 11%, reaching 35,8 million BGN in 2012 compared to 40,3 million BGN in 2011.

Assets

	31.12.2012	31.12.2011	change	share
	BGN '000	BGN '000	%	2012
Non-current assets				
Property, plant and equipment	289 602	236 338	23%	82%
Intangible assets	27 489	27 979	-2%	8%
Investment property	7 110	6 555	8%	2%
Available-for-sale investments	20 520	19 972	3%	6%
Investments in associated companies	566			0%
Loans granted to related parties	748	729	3%	0%
Differed taxes	3 327	1 709		1%
Other non-current assets	1 897	848	124%	1%
	351 259	294 130	19%	47%
Current assets				
Inventories	132 251	126 022	5%	33%
Trade receivables	164 806	136 756	21%	42%
Receivables from related parties	60 691	63 113	-4%	15%
Other receivables and prepayments	22 491	24 332	-8%	6%
Cash and cash equivalents	16 107	32 235	-50%	4%
	396 346	382 458	4%	53%
TOTAL ASSETS	747 605	676 588	10.5%	100%

Total assets increased by 71 million BGN, or 10,5%, reaching 747,6 million BGN, compared to 676,6 as at 31 December 2011 as a result of the increase in both current and non-current assets.

Non-current assets increased by 57,1 million BGN, or 19%, mainly due to the increase in property, plant and equipment by 53,3 million BGN. The most significant impact on the increase in property, plant and equipment have assets in the process of acquisition mostly due the investment in the new solid forms factory, which for 2012 is 50,1 million BGN, while the total funds invested since the beginning of the project amounted to 75,6 million BGN. Additional funds were invested on acquisition of laboratory and production equipment.

Intangible assets fell by 0.5 million BGN, with the most significant expense being the implementation of an integrated information system.

Available-for-sale investments increased by 0,5 million BGN due to a capital increase of Doverie United Holding AD.

Investments in associated companies increased by 0,6 million BGN, compared to 31 December

2011.

Current assets increased by 13,8 million BGN or 4%, reaching 396,3 million BGN as at 31 December 2012 compared to 382,5 million BGN as at 31 December 2011.

Inventories comprise 33% of current assets and increased by 6,2 million BGN compared to 31 December 2011, mainly in the portion of goods (by 1,4 million BGN), materials (by 3,4 million BGN), finished products (by 1,7 million BGN) and unfinished products (by 0,3 million BGN). Semi-finished products decreased by 0,6 million BGN.

Trade receivables, which have a relative share of 42% of current assets, increased by 28,1 million BGN, most significantly in the portion of receivables from customers (27,4 million BGN) and advance payments, which increased by 0,6 million.

Receivables from related parties have a relative share of 15% in current assets and decreased by 2,4 million BGN. The most significant contribution to this decrease have receivables on commercial loans granted with 2,9 million BGN.

Other receivables and prepaid expenses comprise 6% of current assets and decreased by 1,8 million BGN, mainly due to a decrease in awards on litigations by 3,4 million BGN. Cash and cash equivalents decreased by 16,1 million BGN compared to 31 December 2011. As at the end of the current period there are deposits amounting to 0,6 million BGN.

Liabilities and owner's equity

	31.12.2012	31.12.2011	change	share
	BGN '000	BGN '000		2012
OWNERS' EQUITY			%	%
Share capital	132 000	132 000	0%	34%
Reserves	35 687	33 534	6%	9%
Retained earnings	176 527	154 465	14%	45%
	344 214	319 999	8%	88%
NON-CONTROLLING INTEREST	46 302	45 813	1%	12%
TOTAL OWNERS' EQUITY	390 516	365 812	7%	100%

	31.12.2012	31.12.2011	change	share
	BGN '000	BGN '000	%	2012
LIABILITIES				
Non-current liabilities				
Long-term bank loans	57 024	23 280	145%	16%
Liabilities on deferred taxes	7 405	6 531	13%	2%
Liabilities to the personnel upon retirement	2 252	2 389	-6%	1%
Financial leasing liabilities	2 430	1 534	58%	1%
Other non-current liabilities	2 596	1 368	90%	1%
	71 707	35 102	104%	20%
Current liabilities				
Short-term loans from banks and third parties	146 880	151 765	-3%	41%
Short-term part of long-term bank loans	65 674	42 650	54%	18%
Commercial liabilities	57 114	66 134	-14%	16%
Liabilities to related parties	2 306	3 360	-31%	1%
Liabilities to the personnel and for social insurance	6 857	5 487	25%	2%
Liabilities for taxes	2 161	3 046	-29%	1%
Other current liabilities	4 390	3 232	36%	1%
	285 382	275 674	4%	80%
TOTAL LIABILITIES	357 089	310 776	15%	100%
TOTAL OWNERS' EQUITY AND LIABILITIES	747 605	676 588	10.5%	

The owner's equity of the Sopharma Group increased by 24,2 million BGN compared to 31 December 2011 mainly through the achieved net profit for the current period. Equity relating to equity holders of the Company comprise 46% of total equity and liabilities, with a certain improvement of the financial autonomy of the Group.

Non-current liabilities increased by 36,6 million BGN or 100,4%, from 35,1 million BGN at the end of 2011 to 71,7 million BGN at the end of 2012 mainly due to the increase in long-term bank loans by 33,7 million BGN, which is due to the appropriation of funds from an investment loan for the construction of a new solid forms factory.

Deferred taxes liabilities increased by 0,9 million BGN, and other non-current liabilities by 1,2 million BGN as a result of government donations related to contracts for gratuitous financial aid.

Current liabilities increased by 9,7 million BGN or 4% compared to the end of 2011, mainly due to short-term part of long-term bank loans, which increased by 23 million BGN. Liabilities to the personnel and for social insurance – by 1,4 million BGN, and other current liabilities – by 1,2 million BGN. The opposite effect have commercial liabilities, which decreased by 9 million BGN compared to 31 December 2011, mainly due to a decrease in payables to suppliers by 7,1 million BGN. The Group's total liabilities on bank loans increased by 51,9 million BGN

compared to the end of 2011, mostly as a result of the investment in the new solid-forms factory.

Cash flow

	31.12.2012 BGN '000	31.12.2011 BGN '000
Net cash flow from operations	621	52 377
Net cash flow from investment activities	(55 597)	(64 506)
Net cash flow from financial operations	37 961	155
Net increase/(decrease) of cash and cash equivalents	(17 605)	(12 834)
Cash and cash equivalents on January 1	32 235	45 069
Cash and cash equivalents on 31 December	14 630	32 235

Net cash flow from operations as at 31 December 2012 amount to 0,6 million BGN, from investment activities (55,6) million BGN and from financial operations 38 million BGN. As a result of these activities the cash and cash equivalents mark a net decrease by 17,6 million BGN and as at 31 December 2012 amount to 14,6 million BGN, compared to 32,2 million BGN as at the end of 2011.

Financial ratios

	31.12.2012	31.12.2011
ROE ¹	10.2%	12.1%
ROA ²	4.8%	5.5%
Asset turnover ³	0.95	1.00
Current liquidity ⁴	1.39	1.39
Quick ratio ⁵	0.93	0.93
Cash/current liabilities ⁶	0.06	0.12
Owners' equity/liabilities ⁷	1.09	1.18

¹ Net profit belonging to the equity holders of the Company, annualised / arithmetic mean of the equity for the last five quarters

² Net profit belonging to the equity holders of the Company, annualised / arithmetic mean of total assets for the last five quarters

³ Revenues from sales, annualised / arithmetic mean of total assets for the last five quarters

⁴ Current assets / current liabilities

⁵ Receivables+cash/current liabilities

⁶ Cash/current liabilities

⁷ Equity/Liabilities

Information about the shares of Sopharma AD

The total number of shares issued by Sopharma as at 31 December 2012 is 132 million with a nominal value of 1 BGN per share. All issued shares are dematerialized, common and indivisible, under the Articles of Association. All issued shares are of one class. Each share gives equal rights to its holder, in proportion to its nominal value. Sopharma's shares are traded on the official market of the BSE - Sofia and the official market of the Warsaw Stock Exchange. The shares are part of the indices SOFIX, BG40 and BGTR30 on the BSE - Sofia.

The Company's shares are included in the indices Dow Jones STOXX EU Enlarged, Total Market Index 0.11% weight, with a weight of 5% in the Erste Bank Bulgaria Basket, the certificate of Raiffeisenbank - Raiffeisen Osteuropa Fonds and the certificate ABN AMRO SOFIX - Open-end-certificate and the new blue-chip index Dow Jones STOXX Balkan 50 Equal Weighted Index.

Sopharma AD is one of the three Bulgarian companies included in a new index for Central and Eastern Europe (CEE) that WSE started to calculate on 30 May. The index is called WIG-CEE and is the third after the WIG-Poland and WIG-Ukraine, which is based on the origin of the companies by country. WIG-CEE is calculated based on total return and includes income from dividends and subscription rights to shares.

Important information for the shares of Sopharma AD

	31.12.2012	31.12.2011
Total number of issued shares	132 000 000	132 000 000
Number of shares outstanding at the end of the period	128 146 265	129 065 837
Earnings per share in BGN ¹	0,26	0,29
Price per share at the end of the period in BGN	2,139	3,175
Price/Earnings ratio (P/E)	8,10	10,95
Book value per share in BGN ²	2,69	2,479
Price/Book value ratio (P/B)	0,80	1,28
Income from sale of one share in BGN ³	5,32	5.00
Price of one share / Income from sale of one share (P/S)	0,40	0,64
Market capitalization in BGN	282 348 000	419 100 000

¹ Net profit of the company for the last four quarters excluding earnings from non-controlling interest/ average outstanding number of shares

² Common equity of the company as per the last financial report excluding non-controlling interest / number of shares outstanding at the end of the period

³ Income from sales in the last four months / number of outstanding shares as at the end of the period.

Trade with shared of Sopharma AD on Bulgarian Stock Exchange – Sofia AD for the period 01.01-31.12.2012



The preliminary management report of Sopharma Group for 2012 has not been audited.

